|Reference : Thymus dysfunction in the development of type 1 diabetes and endocrine autoimmune diseases|
|Scientific journals : Article|
|Human health sciences : Endocrinology, metabolism & nutrition|
Human health sciences : Immunology & infectious disease
|Thymus dysfunction in the development of type 1 diabetes and endocrine autoimmune diseases|
|Geenen, Vincent [Université de Liège - ULg > > Centre d'immunologie - Embryologie >]|
|Dardenne Olivier [Université de Liège - ULG > Centre d'Immunologie - CIL > > >]|
|[en] Thymus ; Self-tolerance ; Autoimmunity|
|[en] The discovery that thymic epithelium from many species expresses a large repertoire of genes encoding neuroendocrine and other tissue-restricted antigens has radically changed our knowledge of the pathogenic mechanisms underlying the development of organ-specific autoimmune diseases such as type 1 diabetes and autoimmune endocrine diseases. Rather than a breakdown of immunological selftolerance
in periphery, there is mounting evidence that the diabetogenic autoimmune response may first arise from a thymus dysfunction in the central programming of β-cell self-tolerance. Insulin-like growth factor 2 (IGF-2) is the dominant member of the insulin gene/protein family expressed in thymic epithelial cells (TECs) from different species, and Igf2-/- mice fail to programme complete tolerance to insulin.
Based on the homology between insulin, the primary and immunogenic auto-antigen of type 1 diabetes, and IGF-2, the tolerogenic self-antigen of the insulin family, the design of a regulatory/negative self-vaccination for prevention against type 1 diabetes has been proposed and is under development.
|Centre d'Immunologie - CIL|
|Fonds de la Recherche Scientifique (Communauté française de Belgique) - F.R.S.-FNRS ; Eurothymaide FP6 Integrated Project ; Région wallonne : Direction générale des Technologies, de la Recherche et de l'Energie - DGTRE|
|Researchers ; Professionals|
|File(s) associated to this reference|
All documents in ORBi are protected by a user license.